448 related articles for article (PubMed ID: 26392228)
1. TGFβ induces epithelial-mesenchymal transition of thyroid cancer cells by both the BRAF/MEK/ERK and Src/FAK pathways.
Baquero P; Jiménez-Mora E; Santos A; Lasa M; Chiloeches A
Mol Carcinog; 2016 Nov; 55(11):1639-1654. PubMed ID: 26392228
[TBL] [Abstract][Full Text] [Related]
2. (V600E)BRAF promotes invasiveness of thyroid cancer cells by decreasing E-cadherin expression through a Snail-dependent mechanism.
Baquero P; Sánchez-Hernández I; Jiménez-Mora E; Orgaz JL; Jiménez B; Chiloeches A
Cancer Lett; 2013 Jul; 335(1):232-41. PubMed ID: 23435375
[TBL] [Abstract][Full Text] [Related]
3. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer.
Riesco-Eizaguirre G; Rodríguez I; De la Vieja A; Costamagna E; Carrasco N; Nistal M; Santisteban P
Cancer Res; 2009 Nov; 69(21):8317-25. PubMed ID: 19861538
[TBL] [Abstract][Full Text] [Related]
4. Acquired resistance to BRAF inhibition induces epithelial-to-mesenchymal transition in BRAF (V600E) mutant thyroid cancer by c-Met-mediated AKT activation.
Byeon HK; Na HJ; Yang YJ; Ko S; Yoon SO; Ku M; Yang J; Kim JW; Ban MJ; Kim JH; Kim DH; Kim JM; Choi EC; Kim CH; Yoon JH; Koh YW
Oncotarget; 2017 Jan; 8(1):596-609. PubMed ID: 27880942
[TBL] [Abstract][Full Text] [Related]
5.
Jiménez-Mora E; Gallego B; Díaz-Gago S; Lasa M; Baquero P; Chiloeches A
Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34204950
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-150-5p affects cell proliferation, apoptosis, and EMT by regulation of the BRAF
Yan R; Yang T; Zhai H; Zhou Z; Gao L; Li Y
J Cell Biochem; 2018 Nov; 119(11):8763-8772. PubMed ID: 30126001
[TBL] [Abstract][Full Text] [Related]
7. Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFβ signaling.
Knauf JA; Sartor MA; Medvedovic M; Lundsmith E; Ryder M; Salzano M; Nikiforov YE; Giordano TJ; Ghossein RA; Fagin JA
Oncogene; 2011 Jul; 30(28):3153-62. PubMed ID: 21383698
[TBL] [Abstract][Full Text] [Related]
8. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
[TBL] [Abstract][Full Text] [Related]
9. TGFbeta-induced EMT requires focal adhesion kinase (FAK) signaling.
Cicchini C; Laudadio I; Citarella F; Corazzari M; Steindler C; Conigliaro A; Fantoni A; Amicone L; Tripodi M
Exp Cell Res; 2008 Jan; 314(1):143-52. PubMed ID: 17949712
[TBL] [Abstract][Full Text] [Related]
10. β-Catenin Attenuation Inhibits Tumor Growth and Promotes Differentiation in a BRAF
Zou M; BinEssa HA; Al-Malki YH; Al-Yahya S; Al-Alwan M; Al-Jammaz I; Khabar KSA; Almohanna F; Assiri AM; Meyer BF; Alzahrani AS; Al-Mohanna FA; Shi Y
Mol Cancer Ther; 2021 Sep; 20(9):1603-1613. PubMed ID: 34224366
[No Abstract] [Full Text] [Related]
11. Resistance to Src inhibition alters the BRAF-mutant tumor secretome to promote an invasive phenotype and therapeutic escape through a FAK>p130Cas>c-Jun signaling axis.
Kessler BE; Mishall KM; Kellett MD; Clark EG; Pugazhenthi U; Pozdeyev N; Kim J; Tan AC; Schweppe RE
Oncogene; 2019 Apr; 38(14):2565-2579. PubMed ID: 30531837
[TBL] [Abstract][Full Text] [Related]
12. Intestinal epithelial cancer cell anoikis resistance: EGFR-mediated sustained activation of Src overrides Fak-dependent signaling to MEK/Erk and/or PI3-K/Akt-1.
Demers MJ; Thibodeau S; Noël D; Fujita N; Tsuruo T; Gauthier R; Arguin M; Vachon PH
J Cell Biochem; 2009 Jul; 107(4):639-54. PubMed ID: 19479902
[TBL] [Abstract][Full Text] [Related]
13. SNAIL induces epithelial-to-mesenchymal transition and cancer stem cell-like properties in aldehyde dehydroghenase-negative thyroid cancer cells.
Yasui K; Shimamura M; Mitsutake N; Nagayama Y
Thyroid; 2013 Aug; 23(8):989-96. PubMed ID: 23432420
[TBL] [Abstract][Full Text] [Related]
14. c-Met-mediated reactivation of PI3K/AKT signaling contributes to insensitivity of BRAF(V600E) mutant thyroid cancer to BRAF inhibition.
Byeon HK; Na HJ; Yang YJ; Kwon HJ; Chang JW; Ban MJ; Kim WS; Shin DY; Lee EJ; Koh YW; Yoon JH; Choi EC
Mol Carcinog; 2016 Nov; 55(11):1678-1687. PubMed ID: 26456083
[TBL] [Abstract][Full Text] [Related]
15. Bisphenol A at a human exposed level can promote epithelial-mesenchymal transition in papillary thyroid carcinoma harbouring BRAF
Li L; Li H; Zhang J; Gao X; Jin H; Liu R; Zhang Z; Zhang X; Wang X; Qu P; Zhao Y; Lu X
J Cell Mol Med; 2021 Feb; 25(3):1739-1749. PubMed ID: 33469997
[TBL] [Abstract][Full Text] [Related]
16. Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E.
Lee MH; Lee SE; Kim DW; Ryu MJ; Kim SJ; Kim SJ; Kim YK; Park JH; Kweon GR; Kim JM; Lee JU; De Falco V; Jo YS; Shong M
J Clin Endocrinol Metab; 2011 Jan; 96(1):E19-30. PubMed ID: 20926530
[TBL] [Abstract][Full Text] [Related]
17. Tenascin C induces epithelial-mesenchymal transition-like change accompanied by SRC activation and focal adhesion kinase phosphorylation in human breast cancer cells.
Nagaharu K; Zhang X; Yoshida T; Katoh D; Hanamura N; Kozuka Y; Ogawa T; Shiraishi T; Imanaka-Yoshida K
Am J Pathol; 2011 Feb; 178(2):754-63. PubMed ID: 21281808
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of MAPK pathway inhibitors on migration and invasiveness of BRAF(V600E) mutant thyroid cancer cells in 2D and 3D culture.
Ingeson-Carlsson C; Martinez-Monleon A; Nilsson M
Exp Cell Res; 2015 Nov; 338(2):127-35. PubMed ID: 26384551
[TBL] [Abstract][Full Text] [Related]
19.
Zou M; Baitei EY; BinEssa HA; Al-Mohanna FA; Parhar RS; St-Arnaud R; Kimura S; Pritchard C; Alzahrani AS; Assiri AM; Meyer BF; Shi Y
Cancer Res; 2017 Apr; 77(8):2161-2172. PubMed ID: 28242615
[TBL] [Abstract][Full Text] [Related]
20. Novel role for CRK adaptor proteins as essential components of SRC/FAK signaling for epithelial-mesenchymal transition and colorectal cancer aggressiveness.
Franke FC; Slusarenko BO; Engleitner T; Johannes W; Laschinger M; Rad R; Nitsche U; Janssen KP
Int J Cancer; 2020 Sep; 147(6):1715-1731. PubMed ID: 32147820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
